Kyntra Bio (KYNB) Fundamental Analysis: Revenue, Earnings & Valuation

4.57 / 10

Netural

Fundamental score is 4.57/10 (neutral). Strengths include PB‑ROE, Revenue‑MV, Cash‑MV and solid gross margin, while Asset‑MV and income‑tax ratios are weak. Overall, fundamentals are modest, warranting a cautious outlook.

Analysis Checks(8/10)

Revenue-MV

Value-4.61

Score2/3

Weight33.76%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value-78.26

Score2/3

Weight-3.32%

1M Return-1.06%

Inventory turnover ratio

Value0.16

Score2/3

Weight-3.87%

1M Return-1.21%

Gross profit margin (%)

Value91.37

Score2/3

Weight6.28%

1M Return1.69%

PB-ROE

Value6.43

Score3/3

Weight43.17%

1M Return9.74%

Income tax / Total profit (%)

Value0.15

Score1/3

Weight-1.59%

1M Return-0.50%

Fixed assets turnover ratio

Value9306.28

Score3/3

Weight3.55%

1M Return1.06%

Cost of sales ratio (%)

Value8.63

Score2/3

Weight-13.22%

1M Return-4.42%

Asset-MV

Value-0.55

Score0/3

Weight10.81%

1M Return2.69%

Cash-MV

Value0.02

Score2/3

Weight24.45%

1M Return5.94%

Is KYNB undervalued or overvalued?

KYNB scores 4.57/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, 2848.63% net margin, 0.15 P/E ratio, 5.96 P/B ratio, and 481.58% earnings growth, these metrics solidify its Netural investment rating.